[go: up one dir, main page]

MX2018007804A - Analogos de cortistatina y usos de los mismos. - Google Patents

Analogos de cortistatina y usos de los mismos.

Info

Publication number
MX2018007804A
MX2018007804A MX2018007804A MX2018007804A MX2018007804A MX 2018007804 A MX2018007804 A MX 2018007804A MX 2018007804 A MX2018007804 A MX 2018007804A MX 2018007804 A MX2018007804 A MX 2018007804A MX 2018007804 A MX2018007804 A MX 2018007804A
Authority
MX
Mexico
Prior art keywords
human
advantageous
low
cortistatin analogs
administration
Prior art date
Application number
MX2018007804A
Other languages
English (en)
Inventor
Matthew D Shair
Efrem Pelish Henry
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2018007804A publication Critical patent/MX2018007804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan derivados de Cortistatina específicos con propiedades ventajosas para la administración in vivo en un huésped, que incluye un ser humano que lo necesita; estas nuevas especies tienen una farmacocinética ventajosa, baja toxicidad, actividad de hERG de baja a moderada y/o otras propiedades farmacológicas que las hacen destacar entre la clase de Cortistatinas como candidatos superiores para administración humana.
MX2018007804A 2015-12-23 2016-12-21 Analogos de cortistatina y usos de los mismos. MX2018007804A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387246P 2015-12-23 2015-12-23
US201662297494P 2016-02-19 2016-02-19
PCT/US2016/068125 WO2017112815A1 (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Publications (1)

Publication Number Publication Date
MX2018007804A true MX2018007804A (es) 2019-07-04

Family

ID=59091204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007804A MX2018007804A (es) 2015-12-23 2016-12-21 Analogos de cortistatina y usos de los mismos.

Country Status (17)

Country Link
US (1) US20180298024A1 (es)
EP (1) EP3394072A4 (es)
JP (1) JP2019508368A (es)
KR (1) KR20180095051A (es)
CN (1) CN108699085A (es)
AU (1) AU2016377678A1 (es)
BR (1) BR112018012647A2 (es)
CA (1) CA3009324A1 (es)
CL (1) CL2018001733A1 (es)
CO (1) CO2018007535A2 (es)
EA (1) EA201891511A1 (es)
IL (1) IL260123A (es)
MX (1) MX2018007804A (es)
PH (1) PH12018501351A1 (es)
RU (1) RU2018126984A (es)
SG (1) SG11201805092WA (es)
WO (1) WO2017112815A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6785252B2 (ja) 2015-07-02 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式ラクタム及びその使用方法
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
KR20210118812A (ko) * 2018-11-01 2021-10-01 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제
WO2022204534A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642766B2 (en) * 2008-05-05 2014-02-04 Ryan A. Shenvi Synthesis of (+) cortistatin A and related compounds
EP2334686B1 (en) * 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
US20130217014A1 (en) * 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) * 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
KR20160101162A (ko) * 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도

Also Published As

Publication number Publication date
CL2018001733A1 (es) 2018-11-09
EA201891511A1 (ru) 2018-12-28
PH12018501351A1 (en) 2019-02-27
CO2018007535A2 (es) 2018-07-31
WO2017112815A1 (en) 2017-06-29
BR112018012647A2 (pt) 2018-12-04
AU2016377678A1 (en) 2018-07-12
US20180298024A1 (en) 2018-10-18
JP2019508368A (ja) 2019-03-28
EP3394072A1 (en) 2018-10-31
CN108699085A (zh) 2018-10-23
CA3009324A1 (en) 2017-06-29
RU2018126984A (ru) 2020-01-23
KR20180095051A (ko) 2018-08-24
SG11201805092WA (en) 2018-07-30
EP3394072A4 (en) 2019-05-29
IL260123A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
PH12018501351A1 (en) Cortistatin analogs and uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TN2017000555A1 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
MX2016008448A (es) Conjugados de var2csa-farmaco.
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
UA118120C2 (uk) Макроциклічні похідні піридину
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
UY37193A (es) Nuevos compuestos antivíricos
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
WO2016048861A3 (en) Heterocyclic compounds and use thereof
TN2016000490A1 (en) Naphthyridinedione derivatives.
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
WO2014172363A3 (en) Combretastatin analogs
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2018009998A (es) Analogos de cortistatina.